Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 2Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Thoracic 1

Conditions

Hematologic Neoplasms 2Hematologic Diseases 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cytarabine 35Cyclophosphamide 30fludarabine phosphate 24fludarabine 24Rituximab 20Azacitidine 19Methotrexate 17venetoclax 16Peripheral Blood Stem Cell Transplantation 14Dasatinib 12Bendamustine Hydrochloride 12ibrutinib 11Filgrastim 11Busulfan 11Whole-Body Irradiation 10Granulocyte Colony-Stimulating Factor 10Tacrolimus 9Radiotherapy 9Lenalidomide 8Idarubicin 8Decitabine 8Vincristine 7Etoposide 7Dexamethasone 7Daunorubicin 7Cyclosporine 7merphos 6Prednisone 6Melphalan 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × INCB039110 × Other hematologic neoplasm × Clear all
NCT04127721 2020-10-29

Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Other hematologic neoplasm

Hematologic Diseases, Hematologic Neoplasms

NCT02355431 2019-03-08

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Incyte Corporation

Phase 2 Withdrawn
Other hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡